• ELOX share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of ELOX shares has decreased $0.36 since the market last closed. This is a 2.81% drop.

  • Closed at $12.44.

    The stock has since risen $0.06 in after-hours trading.

Key terms

About ELOX

Eloxx Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of novel ribonucleic acid-modulating drug candidates. It focuses on the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Arlington, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $50.21M

    A market capitalization up to $300 million places ELOX in the micro-capitalization category.

Key terms

Smart score

Latest ELOX news

Oct 29, 2026 8:05am ET Eloxx Pharmaceuticals announces FDA clearance of IND application for exaluren by TipRanks Oct 28, 2026 7:20am ET Eloxx Pharmaceuticals price target lowered to $40 from $43 at Guggenheim by TipRanks Oct 22, 2026 6:34am ET Eloxx Pharmaceuticals Advances Leadership and Phase 2 Kidney Trial by TipRanks Oct 20, 2026 9:40am ET Eloxx Pharmaceuticals appoints T.R. Srinivas as CMO by TipRanks Oct 20, 2026 9:35am ET Eloxx Pharmaceuticals finalizes Phase 2 EXPRESS study design by TipRanks Oct 15, 2026 7:15am ET Eloxx Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald by TipRanks Oct 15, 2026 6:36am ET Eloxx Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald by TipRanks Sep 18, 2026 8:30am ET Analysts’ Top Healthcare Picks: BridgeBio Oncology Therapeutics (BBOT), Entera Bio (ENTX) by TipRanks Sep 18, 2026 8:26am ET Leerink bullish on Eloxx Pharmaceuticals, initiates with an Outperform by TipRanks Sep 18, 2026 6:10am ET Eloxx Pharmaceuticals initiated with an Outperform at Leerink by TipRanks Sep 11, 2026 5:35pm ET Eloxx Pharmaceuticals files to sell 600,000 shares of common stock for holders by TipRanks Sep 11, 2026 7:35am ET Eloxx Pharmaceuticals says first patients dosed in Phase 2b Exact Study by TipRanks Aug 24, 2026 7:20am ET Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL) by TipRanks Aug 20, 2026 6:20am ET Eloxx Pharmaceuticals initiated with a Buy at Lucid Capital by TipRanks Aug 12, 2026 6:35am ET Eloxx Maintained at Buy as Strong Exaluren Pipeline and Solid Cash Runway Support Unchanged $40 Price Target by TipRanks

No recent press releases are available for ELOX

ELOX Financials

1-year income & revenue

  • ELOX total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Net income: -$6.00M (1Y), -$4.50M (Q2)

    Net Income increased 83.38% since last year and decreased 19.93% since last quarter.

  • Earnings per share: -$5.34 (1Y), -$0.66 (Q2)

    EPS increased 97.08% since last year and increased 22.59% since last quarter.

Key terms

ELOX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ELOX Competitors

$ Market capP/E ratio$ Price1d change52-week range
  • How competitors are chosen

    ELOX's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $50.21M

    A market capitalization up to $300 million places ELOX in the micro-capitalization category.

Key terms

Latest investing news